The alterations in the protein levels of Bcl2, cleaved PARP, cyclin D1, CDK2, and CDK4 further confirmed that the combination of gefitinib and regorafenib indeed promoted cell apoptosis and inhibited the proliferation of regorafenib-resistant HCC cells (Figure 3E). Here, BCL2 is linked to hepatocellular carcinoma.